GLORIMARI NIEVES: Open Payments
NPI 1700420312 · MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,209 in 50 payments from 15 companies in 2025. Trend: 2023 $765 · 2024 $843 · 2025 $1,209
Food & beverage: $1,209
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 5 | $311 |
| Daiichi Sankyo Inc. | 8 | $184 |
| Lilly USA, LLC | 12 | $155 |
| Merck Sharp & Dohme LLC | 6 | $127 |
| PFIZER INC. | 4 | $86 |
| TerSera Therapeutics LLC | 3 | $82 |
| Gilead Sciences, Inc. | 2 | $49 |
| Stemline Therapeutics Inc. | 2 | $44 |
| Janssen Biotech, Inc. | 2 | $40 |
| Novartis Pharmaceuticals Corporation | 1 | $29 |
Products named: ENHERTU, VERZENIO, KEYTRUDA, IBRANCE, Zoladex, Orserdu, KISQALI, Itovebi.
Industry payments across FL — which companies pay providers there.
